Syfovre claims for vision loss and blindness involving retinal vasculitis diagnosed after a patient’s first Syfovre injection are being filed as drug injury lawsuits. The basis for these product liability Syfovre lawsuits is the drug company Apellis Pharmaceuticals failed to warn about retinal vasculitis as a side effect until it revised the Syfovre drug label in November 2023.
The FDA approved Syfovre (pegcetacoplan) as an eye injection treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in February 2023.
A December 2023 article on Syfovre-related vision loss and blindness involving retinal vasculitis, co-authored by the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee reported that at least 13 patients had developed vision loss and blindness after being injected with Syfovre earlier in 2023. Specifically, those 13 patients developed retinal vasculitis after their first Syfovre injection.
As mentioned previously, while Syfovre was initially available for use in February 2023, it was not until November 2023 that Apellis added new Syfovre warnings for retinal vascular occlusion and retinal vasculitis cases associated with Syfovre injections to the Syfovre drug label. This time-lapse is a central part of the Syfovre claims for vision loss and blindness that are being filed.
In more detail, Syfovre injection side effects include occlusive retinal vasculitis and non-occlusive retinal vasculitis. These types of eye inflammation result in vision loss and potentially cause blindness.
From this July 19, 2024 Managed Healthcare Executive news report, “The Syfovre Balancing Act. The Retinal Vasculitis Risk Is Real But Research Also Points to Benefits | ASRS 2024“, we get the most recent findings about patients who were treated with Syfovre and then diagnosed with retinal vasculitis: “The combined results of two real-world evidence studies presented Thursday put the risk of developing retinal vasculitis at about 1 in every 1,330 patients.”
We are handling Syfovre claims for vision loss and blindness involving retinal vasculitis diagnosed after a patient’s first Syfovre injection. These personal injury cases are drug injury lawsuits filed against Apellis Pharmaceuticals. More precisely, these Syfovre lawsuits are based on product liability law for the alleged failure to warn about retinal vasculitis as a Syfovre side effect promptly. As such, these Syfovre lawsuits are not filed against the patients’ eye doctors.
We offer a free online Case Evaluation concerning these Syfovre claims for vision loss and blindness, or you can call us toll-free at 800-426-9535.
[View article at original source]Syfovre
Free Case Evaluation
Strictly Confidential, No Obligation